Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: A randomised phase II trial

Radiotherapy and Oncology

Volumn 84, Issue 1, 2007, Pages 23-25

  De Ruysscher, Dirk ^a,b   Bussink, Johan ^c   Rodrigus, Patrick ^d   Kessels, Alfons ^b   Dirx, Miranda ^e   Houben, Ruud ^a   Wanders, Rinus ^a  

^a MAASTRO CLINIC   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^e Maastricht UMC+ Comprehensive Cancer Centre   (Netherlands)

Author keywords

Celecoxib; COX 2; NSCLC; Phase II; Radiotherapy; Randomised

Indexed keywords

CELECOXIB; PLACEBO;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRAZOLES; RADIATION-SENSITIZING AGENTS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 34447102890     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.05.008     Document Type: Article

References (19)

1. Dawson S.J., Michael M., Biagi J., et al. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs (2006) [Epub ahead of print]
2. Deeks J.J., Smith L.A., and Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Br Med J 325 (2002) 619-623
3. Dohadwala M., Luo J., Zhu L., et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276 (2001) 808-812
4. Gaffney D.K., Winter K., Dicker A.P., et al. A phase II study of acute toxicity for Celebrex trademark (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys (2006) [Epub ahead of print]
5. Gallo O., Milas L., Mason K., et al. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxidase-2 enzyme. J Natl Cancer Inst 92 (2000) 346-347
6. Ganswindt U., Budach W., Jendrossek V., et al. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. Radiat Oncol 10 (2006) 1-9
7. Gross N., Holloway N., Narine K., et al. Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis. Radiat Res 127 (1991) 317-324
8. ICRU Report 50. Prescribing, Recording, and reporting Photon Beam Therapy. International Commission on Radiation Units and Measurements. 1993.
9. Khuri F.R., Wu H., Lee J.J., et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 4 (2001) 861-867
10. Kishi K., Petersen S., Petersen C., et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60 (2000) 1326-1331
11. Liao Z., Komaki R., Milas L., et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11 (2005) 3342-3348
12. Lilenbaum R., Socinski M.A., Altorki N.K., et al. Randomized phase II trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan with or without Celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 24 (2006) 4825-4832
13. Park J.S., Jun H.J., Cho M.J., et al. Radiosensitivity enhancement by combined treatment of Celecoxib and Gefitinib on human lung cancer cells. Clin Cancer Res 12 (2006) 4989-4999
14. Psaty B.M., and Furberg C.D. COX-2 inhibitors - lessons in drug safety. N Engl J Med 352 (2005) 1133-1135
15. Rubin P., and Wasserman T.H. International clinical trials in radiation oncology: the late effects of toxicity scoring. Int J Radiat Oncol Biol Phys 114 (1988) S29-S38
16. Soslow R.A., Dannenberg A.J., Rush D., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637-2645
17. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
18. Tochner Z., Barnes M., Mitchell J.B., et al. Protection by indomethacin against acute radiation esophagitis. Digestion 47 (1990) 81-87
19. Williams C., Tsujii M., Reese J., et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105 (2000) 1589-1594